Contents

Contributors, vii
Acknowledgement to Cochrane Library, xi

1 Practising evidence-based respiratory medicine, 1
   Section Editor: Michael Abramson

1.1 Introduction, 3
   Brian H Rowe and Terry P Klassen

1.2 Diagnostic strategies, 11

1.2.1 Presenting symptoms, 13
   Michael Abramson

1.2.2 Lung function testing, 25
   David P Johns and Alan J Crockett

1.2.3 Chest radiographic and computerized tomography patterns, 37
   Johny A Verschakelen

1.2.4 Diagnostic strategies in pulmonary embolism: an evidence-based approach, 63
   Martin Riedel

1.2.5 Screening for lung cancer, 81

1.3 Therapeutics: general issues, 89

1.3.1 Adherence and self-management, 91
   Liesl M Osman and Michael E Hyland

1.3.2 Corticosteroid-induced osteoporosis, 107
   Michael L Burr and Michael Stone

1.3.3 Helping people to stop smoking, 115
   Tim Lancaster

2 Asthma, 121
   Section Editor: Peter G Gibson

2.1 Acute exacerbations, 123
   Brian H Rowe

2.2 Chronic therapy: β-agonists, short-acting, long-acting β2-agonists, 135
   Haydn Walters and Julia Walters

2.3 Inhaled corticosteroids in the treatment of asthma, 147
   Nick Adams

2.4 Anti-leukotrienes, 169
   Francine M Ducharme

2.5 Asthma education, 183
   Peter G Gibson and Heather Powell

2.6 Non-pharmacological and complementary interventions to manage asthma, 193
   Guy B Marks, Brett G Toelle and Cassandra A Slader

2.7 Difficult asthma, 205
   Peter A B Wark

2.8 Novel therapies in asthma: long-acting β2-agonists inhaled corticosteroids, 217
   Nicola A Marks and Philip W Ind

3 Chronic obstructive pulmonary disease, 231
   Section Editor: Richard Wood-Baker

3.1 Chronic obstructive pulmonary disease — acute exacerbations, 233
   Brian H Rowe and Irvin Mayers

3.2 Anticholinergic bronchodilators in chronic obstructive pulmonary disease therapy, 245
   Alicia R Zuwallack and Richard L Zuwallack

3.3 Inhaled corticosteroids in chronic obstructive pulmonary disease, 257
   Christine Jenkins

3.4 Combination of inhaled corticosteroids and long-acting β2-agonists in chronic obstructive pulmonary disease, 267
   Paul W Jones
3.5 Systemic corticosteroids in stable chronic obstructive pulmonary disease, 277
Richard Wood-Baker

3.6 Lung volume reduction, 285
Tudor P Toma and Duncan M Geddes

4 Infection, 299
   Section Editor: Jimmy Volmink
4.1 Bronchitis and sinusitis, 301
   Tom Fahey
4.2 Community-acquired pneumonia, 309
   Jihendra N Pande, Juhi Dhar and G Sowmya
4.3 Pulmonary tuberculosis, 321
   Jimmy Volmink and Colleen Murphy
4.4 Influenza: vaccination and treatment, 335
   Fotini B Karassa and John P A Ioannidis
4.5 Bronchiectasis, 349
   John Kolbe
4.6 Adult cystic fibrosis, 361
   John Kolbe
4.7 Antibiotics in chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis, 389
   Ian A Yang, Samuel T Kim and Scott C Bell

5 Respiratory failure/sleep-disordered breathing, 415
   Section Editor: Michael Hensley
5.1 Respiratory rehabilitation, 417
   Yves Lacasse, François Maltais and Roger S Goldstein
5.2 Non-invasive ventilation in acute respiratory failure, 429
   Peter Wark
5.3 Non-invasive positive pressure ventilation in stable patients with chronic obstructive pulmonary disease. What is the evidence?, 439
   Peter J Wijkstra
5.4 The treatment of the obstructive sleep apnoea–hypopnoea syndrome, 447
   Michael J Hensley and Cheryl D Ray
5.5 Long-term oxygen therapy for chronic respiratory failure in chronic obstructive pulmonary disease, 463
   Peter G Gibson

6 Diffuse lung disease/pleural disease/thromboembolism, 473
   Section Editor: Ulrich Costabel
6.1 Diffuse lung disease, 475
   6.1.1 The treatment of cryptogenic fibrosing alveolitis, 477
      Barry Plant and Jim Egan
   6.1.2 Evidence-based approach to treatment of sarcoidosis, 491
      Robert P Baughman and Olof Selroos
   6.1.3 Hypersensitivity pneumonitis, 509
      Yves Lacasse and Yvon Cormier
6.2 Pleural disease, 521
   Richard Light
6.3 Therapy of pulmonary thromboembolism: an evidence-based approach, 537
   Martin Riedel
6.4 Pulmonary hypertension, 559
   Horst Olschewski

Index, 573